Mirum Pharmaceuticals, Inc.
MIRM· Nasdaq
Released Aug 5, 2026, after the close
10-Q filed Aug 5, 2026, 36 days after period end · 0001759425-26-000045
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $176.24M | $127.79M | $77.88M | $37.50M |
| Net Income | -$67.23M | -$5.86M | -$24.64M | -$74.04M |
| EPS Diluted |
Mirum Pharmaceuticals, Inc. · CIK 1759425 · Engraved from SEC EDGAR
| -$1.06 |
| -$0.12 |
| -$0.52 |
| -$1.94 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.